SAGE Therapeutics (SAGE), Biogen (BIIB) ZURZUVAETM approved in PPD, receives CRL for MDD

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. FIX

Go back to SAGE Therapeutics (SAGE), Biogen (BIIB) ZURZUVAETM approved in PPD, receives CRL for MDD

Oppenheimer Reiterates Perform Rating on Sage Therapeutics (SAGE)

August 7, 2023 4:56 PM EDT

Oppenheimer analyst Jay Olson reiterated a Perform rating and $20.00 price target on Sage Therapeutics (NASDAQ: SAGE)

The analyst comments "SAGE is focused on delivering newly-approved Zurzuvae to PPD patients while accelerating development of pipeline assets and rationalizing OpEx spending. We... More

SAGE Therapeutics (SAGE) sinks nearly 50% as trading resumes following CRL

August 7, 2023 7:12 AM EDT

SAGE Therapeutics (NASDAQ: SAGE) sinks 47% as trading resumes after FDA approval for ZURZUVAETM in postpartum depression (PPD) but a CRL for major depressive disorder (MDD).

... More

Biogen (BIIB) PT Lowered to $290 at Oppenheimer on CRL for MDD

August 7, 2023 6:28 AM EDT

Oppenheimer analyst Jay Olson lowered the price target on Biogen (NASDAQ: BIIB) to $290.00 (from $360.00) while maintaining a Outperform rating.

The analyst commented, "The MDD CRL for zuranolone deals BIIB a major blow but not a knockout. We expected BIIB to bolster topline growth... More